Revvity

RVTY · NYSE

$156.01+$5.07 (+3.36%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $150.94

RVTY analyst rating

HoldConsensus of 16 analysts over the last 12 months. 31% rate it a buy.

Strong buy0
Buy5
Hold11
Underperform0
Sell0

12-month price target · 18 analysts

Average $134.53 (−13.8% downside)

Low: $111.10
Now: $156.01
High: $173.25

Upgrades and downgrades

The latest rating actions, newest first

RVTY analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Oct 13, 2026	Maintains	Buy	$130.00 → $175.00	61%
Barclays	Oct 7, 2026	Maintains	Equal-Weight	$115.00 → $160.00	54%
William Blair	Oct 6, 2026	Initiates	Outperform	—	50%
UBS	Sep 9, 2026	Initiates	Buy → Neutral	$120.00 → $140.00	59%
Keybanc	Sep 4, 2026	Maintains	Overweight	$125.00 → $165.00	49%
RBC Capital	Sep 1, 2026	Initiates	Sector Perform	$135.00	59%
Evercore ISI Group	Aug 5, 2026	Maintains	Outperform	$125.00 → $126.00	52%
Evercore ISI Group	Jul 6, 2026	Maintains	Outperform	$110.00 → $125.00	52%
Bernstein	Jun 26, 2026	Initiates	Market Perform	$115.00	65%
Wolfe Research	Jun 2, 2026	Initiates	Peer Perform	—	45%

The case for and against

Updated Oct 15, 2026

Bull case

Revvity is supported by a strengthening fundamental backdrop as FY26 guidance was raised from 2-3% organic growth to 4-5%, while management also signaled improving markets, intact biotech funding, and early AI-driven demand that is lifting screening orders and pre-clinical activity. Its Life Sciences business, about 50% of revenue, is well positioned for a recovery in pharma/biotech investment, and the company’s software and diagnostics franchises add durable, higher-margin growth engines with signals software embedded at 47 of the top 50 pharma and biotech companies and reproductive health holding 90%+ market share. In addition, a mid-30s operating margin goal, pro forma FY26 adjusted operating margin around 28.4%, and a 17x FY26 P/E valuation with China IDx divestiture reducing risk all reinforce a favorable long-term outlook.

Bear case

Revvity is viewed negatively because its recent growth mix leans on a few temporary catalysts rather than durable fundamentals, with Diagnostics up 11% organic in 2Q but Reproductive Health’s strength tied to the GEL contract that annualizes in Q4 ’26 and then creates tougher comparisons. The China immunodiagnostics divestiture removes a persistent drag and policy risk, yet the fact that China once represented about 45% of Euroimmun sales at acquisition in 2017 underscores how much prior growth was exposed to a challenged market now facing mid-2025 DRG reimbursement reform and a closing expected by end of 2027. Meanwhile, Signals software is too small at roughly 9% of revenue to offset slower core growth, while structural headwinds such as declining birth rates, softer reagent recovery, and rising competition limit confidence in sustained outperformance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.